CSL Limited [ASX:CSL] is a biopharmaceutical company involved in research, manufacturing and product marketing. CSL develops a range of products to treat viral and bacterial illnesses, bleeding disorders and coagulation disorders such as blood clotting.
The CSL share price closed 4.73% higher on Thursday.
On Wednesday, CSL announced its 2014 end of financial year results. Net Profit was up $1.31 billion, 7.8% higher than the previous year. In addition, revenue was $394.8 million higher.
CSL also declared an interim dividend of 60 cents. Making the full year dividend $1.13. Up from $1.02 in 2013.
And finally, even though CSL just completed a $950 million buy back, they are teasing the market, suggesting the company may consider another $950 million buy back this financial year.
Free Reports:
The financial results pushed CSL’s share price back over $70 for the first time in two months. Prior to this, the stock was falling and looking like it was going to test a very sketchy technical support level of $62.
The net profit result slightly surpassed CSL’s own expectation of 7% for 2014. For this financial year, CSL estimate a 12% net profit.
Some analysts believe CSL’s market share will be tested this year and next. Baxter International Inc [NYSE:BAX] is soon to have immunoglobin product HyQvia approved in the US. This product could take market share from CSL’s Hizentra.
After trading above $70 today, expect some profit taking over the next couple of days as investors cash in on this recent high. However CSL still remains a solid defensive stock.
Shae Smith+
Editor, Money Weekend
The post Why the CSL Share Price Rose Today appeared first on Stock Market News, Finance and Investments | Money Morning Australia.